Bryce Point Capital LLC Purchases New Position in United Therapeutics Corporation $UTHR

Bryce Point Capital LLC acquired a new position in shares of United Therapeutics Corporation (NASDAQ:UTHR) during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 1,365 shares of the biotechnology company’s stock, valued at approximately $572,000.

Other institutional investors and hedge funds have also made changes to their positions in the company. WealthCollab LLC grew its stake in United Therapeutics by 55.9% during the 2nd quarter. WealthCollab LLC now owns 106 shares of the biotechnology company’s stock worth $30,000 after buying an additional 38 shares during the last quarter. Rakuten Securities Inc. boosted its holdings in shares of United Therapeutics by 76.7% in the second quarter. Rakuten Securities Inc. now owns 106 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 46 shares during the period. Wilmington Savings Fund Society FSB boosted its holdings in shares of United Therapeutics by 125.6% in the third quarter. Wilmington Savings Fund Society FSB now owns 88 shares of the biotechnology company’s stock valued at $37,000 after acquiring an additional 49 shares during the period. Geneos Wealth Management Inc. increased its holdings in shares of United Therapeutics by 141.7% in the 1st quarter. Geneos Wealth Management Inc. now owns 145 shares of the biotechnology company’s stock valued at $45,000 after acquiring an additional 85 shares during the period. Finally, True Wealth Design LLC increased its holdings in shares of United Therapeutics by 738.5% in the 3rd quarter. True Wealth Design LLC now owns 109 shares of the biotechnology company’s stock valued at $46,000 after acquiring an additional 96 shares during the period. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

UTHR has been the topic of several research reports. UBS Group raised their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research report on Tuesday, January 6th. Royal Bank Of Canada raised their price target on United Therapeutics from $569.00 to $587.00 and gave the stock an “outperform” rating in a report on Thursday, October 30th. Jefferies Financial Group restated a “buy” rating and issued a $575.00 price target on shares of United Therapeutics in a research report on Wednesday, November 19th. Wells Fargo & Company increased their price objective on United Therapeutics from $414.00 to $423.00 and gave the stock an “equal weight” rating in a research report on Thursday, October 30th. Finally, HC Wainwright lifted their target price on United Therapeutics from $500.00 to $525.00 and gave the company a “buy” rating in a research note on Thursday, October 30th. Eight analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $509.50.

Insiders Place Their Bets

In other United Therapeutics news, COO Michael Benkowitz sold 22,500 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $470.43, for a total value of $10,584,675.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 498,714 shares of company stock worth $240,366,488 in the last quarter. Corporate insiders own 10.30% of the company’s stock.

United Therapeutics Stock Performance

United Therapeutics stock opened at $473.12 on Tuesday. The company has a market cap of $20.37 billion, a P/E ratio of 17.93, a price-to-earnings-growth ratio of 2.58 and a beta of 0.85. United Therapeutics Corporation has a one year low of $266.98 and a one year high of $519.99. The business has a fifty day moving average of $486.61 and a two-hundred day moving average of $429.50.

United Therapeutics Company Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.